Rakours 223Ra, an anticancer drug developed in Russia, has been introduced into medical practice. Based on the radionuclide radium-223, this innovative treatment specifically targets bone metastases, promising to reduce pain and significantly improve the quality of life for patients with certain cancers.
The anticancer drug « Rakours 223Ra », developed by the Federal Research Clinical Center for Radiology and Oncology of the Federal Medical-Biological Agency (FMBA) of Russia, has been introduced into medical practice, the FMBA announced on its Telegram channel on January 14. According to the statement, the first batch has already been delivered to Russian medical institutions. The drug has been state-registered and is now authorized for clinical oncology use.

At the heart of this innovation is the radionuclide radium-223. The FMBA explained that the radioactive radiation of 223Ra acts in a targeted manner on bone metastases, reducing pain and improving patients' quality of life. Rakours 223Ra is intended for the treatment of certain types of cancer, primarily those that have metastasized to the bones.
The FMBA emphasized the strategic importance of introducing this medication for the Russian healthcare system. Its arrival marks an important step in the development of the radiopharmaceutical sector and also contributes to ensuring technological sovereignty. The agency indicated that the introduction of Rakours 223Ra into medical practice is a major event for Russian medicine, opening prospects for more effective treatment of patients with cancer.
In Russia, active research is being conducted in the field of treating various types of cancer. Last summer, the FMBA submitted the necessary documents to the Russian Ministry of Health to obtain authorization for conducting clinical trials on an anticancer vaccine intended for the treatment of colorectal cancer. Veronika Skvortsova, former Russian Minister of Health and current director of the FMBA, emphasized that this medication had demonstrated "great effectiveness" in slowing tumor growth and reducing the size of cancerous formations.

Last September, Alexander Gintsburg, director of the Gamaleya Research Institute of Epidemiology and Microbiology, announced that Russian scientists were ready to begin treating patients using a Russian mRNA-based cancer vaccine. This medication, developed by the Gamaleya Institute in cooperation with the Guertsen Institute and the National Blokhine Center, is based on neoantigens and must be individually manufactured for each patient, according to the genetic profile of their tumor.